Julian English

Eli Lilly announces three acquisitions to build infectious disease portfolio

Positive topline results from a phase 3 trial for VGX-3100 in cervical dysplasia patients announced by ApolloBio, INOVIO’s partner in China

Innovent Biologics’ new bispecific fusion protein demonstrates robust survival benefits in long-term follow-up study in advanced immunotherapy-resistant non-small-cell lung cancer

US FDA IND clearance for localised fat reduction candidate, a second global phase 3 study of Caliway’s CBL-514

Inhibrx provides clinical update on ozekibart in late line colorectal cancer

US$ 8.5 million investment in malaria and other R&D projects planned among pharma giants

Positive phase 1 data for RAG-17 in amyotrophic lateral sclerosis patients with mutations in the superoxide dismutase 1 gene

New non-compromise early-phase progression accelerator launched

AbbVie announces positive CHMP opinion for Maviret (glecaprevir/pibrentasvir) for the treatment of acute Hepatitis C infection

Neuvoir awarded Smart:Scotland grant to advance AI feasibility work for NHS generic medicines access